PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 7514811

[Multiple sclerosis--what should be done?].

J Kesselring
View original source ↗Export metadata ↓

Abstract

Major progress in MS-research has been achieved in recent years concerning diagnosis and differential diagnosis, pathogenetic mechanisms and prognostic indicators. Symptomatic treatment and prevention of complications help to improve quality of life and to prolong expected duration of life. Treatment trials intended to influence the course of the disease must still be considered experimental. Comprehensive rehabilitation remains the cornerstone of long-term management in MS. First results of carefully designed placebo-controlled double-blind studies, however, justify the expectation, that more efficient measures to influence the course of the disease will be available in the near future.

Explore related subjects

Combined Modality TherapyHumansImmunosuppressive AgentsMultiple SclerosisNeurologic ExaminationPalliative CareEnglish AbstractJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

J Kesselring. 1993. [Multiple sclerosis--what should be done?].. https://pubmed.ncbi.nlm.nih.gov/7514811/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

[Fibromyalgia. Diagnostics--disease approach--therapy].

Fibromyalgia is a complex of symptoms predominantly affecting females and consisting of widespread pain. Etiology and pathogenesis are not sufficiently known yet, however, there is the assumption that fibromyalgia is looked at as being an illness with biological, psychological, and social aspects. Therefore, the treatment of fibromyalgia calls for a multimodal therapy approach. The importance of fibromyalgia has been recognized within the German health system by creating the new ICD code M79.70 and by assigning fibromyalgia its own rheumatologic DRG (I79Z). In future research of fibromyalgia special attention needs to be placed upon gender-specific problems.

Combined Modality Therapy↗
PubMed2007

Lack of survival benefit of post-operative radiation therapy in prostate cancer patients with positive lymph nodes.

Randomized data from SWOG 8794 and EORTC 22911 confirm the benefit of post-operative radiation therapy (RT) for selected patients with pT3 prostate cancer (CaP) after radical prostatectomy (RP). However, data regarding the potential benefit of RT for patients post-RP with positive lymph node (+LN) involvement are limited. We analyzed the Surveillance Epidemiology End Results (SEER) registry for population-based data on efficacy of post-operative RT for +LN patients after RP. As LN data have only been captured by SEER since 1988, we analyzed data for 1988-1992, with specific attention to 10-year relative survival (defined as observed survival divided by the survival of a gender-, age- and race-matched population cohort without disease). Specifically analyzed were data for 1921 patients with nonmetastatic prostate cancer who underwent surgery alone, or surgery followed by RT, and who had +LNs documented. SEER does not code the interval between surgery and RT, so the ratio of patients receiving salvage versus adjuvant therapy is unknown. Using follow-up data through 2002, post-diagnosis survival was examined by number of +LNs. There was no significant relative survival benefit for +LN patients receiving post-operative RT (chi(2)P=0.270). These data do not support routine use of post-operative RT for patients with +LNs in the surgical specimen.

Combined Modality Therapy↗